Regulatory approval is only one marker of success for biotherapeutics. Biotherapeutics must also be commercially feasible. Too high a price tag can lead to limited availability to the targeted patient ...

China has invested more than $120 billion in overseas mining and upstream processing since 2023, accelerating a state-backed push to secure the raw materials underpinning the global energy transition, ...

The biopharmaceutical sector is transitioning from reactive off-line quality control to a proactive quality by design (QbD) framework. Process analytical technology (PAT) enables this shift through ...

Polyethylenimine (PEI)-assisted transfection is a mainstay in upstream processing (USP) for viral vector manufacturing. But recent developments are shifting it from a ...